In the News

Diabetes incidence projected to increase among youth in U.S.

A modeling study using data from 2002-2017 found that incidence of type 1 and type 2 diabetes could increase in those under age 20 years by up to 65% and 673%, respectively, over the next three decades, although confidence intervals were wide.

HbA1c at diagnosis may predict metformin failure, study finds

A model that included baseline HbA1c level, age, sex, and race/ethnicity had high discrimination for predicting failure risk, with the strongest association seen for HbA1c.

Fiber-enriched formula linked to improved health-related quality of life, HbA1c in type 2 diabetes

Participants who consumed prebiotic fiber-enriched nutritional shakes had improved measures of health-related quality of life and reduced HbA1c level at 12 weeks compared to those who consumed placebo shakes, an industry-funded trial found.

MKSAP quiz: Frequent hypoglycemia

This month's quiz asks readers to evaluate a 38-year-old woman for frequent episodes of hypoglycemia. She was diagnosed with type 1 diabetes 15 years ago and has been on continuous subcutaneous insulin infusions with an insulin pump for 13 years.

ADA updates diabetes standards of care for 2023

The American Diabetes Association (ADA) has changed its recommendations on hypertension cutoffs, use of statins, and treatment of patients with diabetes and chronic kidney disease, among other topics.

Low-carb diet improved diabetes control, but effects didn't last

Patients with type 2 diabetes randomized to a low-carb, high-fat diet for six months showed more improvement in HbA1c level than those assigned to a low-fat, high-carb diet, a Danish trial found.

Case report involving diabetes published

The report details how unrecognized type 1 diabetes predisposed a 24-year-old patient with a recent type 2 diabetes diagnosis to develop sodium-glucose cotransporter-2 inhibitor therapy-induced euglycemic diabetic ketoacidosis.

Glargine and liraglutide improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin, while liraglutide reduced CV events vs. glargine, glimepiride, or sitagliptin

Although microvascular complications and death were not materially different among the four treatment groups in a recent trial, the results do allow inferences about the role of sulfonylureas and dipeptidyl peptidase-4 inhibitors in practice, an ACP Journal Club commentary said.

In T1DM, open-source automated insulin delivery increased glucose time in target vs. sensor-augmented pumps

A challenge to wider use of the open-source systems to manage type 1 diabetes (T1DM) is that they are not approved by the FDA and thus require clinicians to be willing to learn from and support their patients, said an ACP Journal Club commentary.

In type 2 diabetes, the BT-001 smartphone app reduced HbA1c more than a control app at 90 d

The availability of an app that delivers cognitive behavioral therapy to patients with diabetes could have meaningful clinical effects, but it remains to be seen whether behavior changes are sustained long-term, an ACP Journal Club commentary said.